TCT-98 Clinical Outcomes at 1 Year with a Repositionable Self-Expanding Transcatheter Aortic Valve  by Manoharan, Ganesh et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B45AV stenosis unsuitable for surgery. We are reporting 6 month out-
comes in TAVR pts with a failed surgical bioprosthesis who were un-
suitable for open surgery.
METHODS The CoreValve US Expanded Use Study is a prospective, non-
randomized, single arm study that evaluates safety and effectiveness of
TAVR in complex subsets of extreme risk pts including those who are
symptomatic with failed surgical bioprosthesis. Baseline echocardio-
graphic data were reported by the sites, while an independent core lab
evaluated all follow-up ﬁndings. The primary endpoint was a composite
of all-cause mortality or major stroke rate at 1 year.
RESULTS From Mar 2013 – Oct 2014, 143 pts had an attempted
implant. Surgical failure mode was stenosis 59%, regurgitation 24%,
combined 17%. 141/143 (98.6%) pts had successful TAVR implantation
with 2 aborted procedures. Pts were elderly 77  11 years, 66% were
men, STS PROM 9.4  6% and severely symptomatic (NYHA III/IV
87%). All-cause mortality or major stroke at 6 mo was 10.7% (mortality
9%, major stroke 1.8%). 6mo Mod/Sev PVL 1.2% & NYHA III/IV 3.4%.
Permanent pacemaker rate was 8.3%.
CONCLUSIONS CoreValve TAVR in pts with failed surgical bio-
prosthesis at extreme risk for surgery was associated with a low 6 mo
mortality and stroke rate, signiﬁcant reduction in aortic valve gradi-
ents, and a low incidence of moderate/severe PVL and NYHA III/IV
failure.
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BACKGROUND Transcatheter aortic valve replacement has become
the default treatment for patients with severe aortic stenosis at
extreme or high risk for surgery. Extrapolation of the safety and ef-
ﬁcacy established in the CoreValve US Pivotal trials has not been
conﬁrmed after regulatory approval. The objective of this study was to
report the 30-day clinical outcome of patients treated with the Cor-
eValve self-expanding bioprostheses in commercial practice.
METHODS A total of 4913 patients with severe aortic stenosis
implanted with the self-expanding CoreValve at 186 US centers be-
tween January 2014 and March 2015 were included in the Trans-
catheter Valve Therapies (TVT) Registry (extreme risk (ER), 41.5%;
high risk (HR), 53.3%; intermediate risk, 3.6%; other; 1.6%). Patientswere followed for at least 30 days for Valve Academic Research Con-
sortium criteria for mortality and major complications.
RESULTS The 30-day results of the TVT Registry are found in the Table.
A transfemoral approach was used in 89.4% of patients. CoreValve sizing
recommended by CTA included: 23 mm, 4.3%; 26 mm, 22.4%; 29 mm,
38.8%; 31 mm, 34.5%. For discussion, the combined results of the
CoreValve US Pivotal Extreme Risk and High Risk Trials are provided
(Popma JACC 2014, Adams, NEJM 2014) (Table). No statistical
comparisons were performed with the TVT Registry due to the differing
patient populations, data collection and enrollment periods.
CONCLUSIONS This ﬁrst report of the TVT Registry provides assur-
ance of the early safety and effectiveness of the CoreValve self-
expanding bioprosthesis in clinical practice. Longer-term follow-up is
needed to establish the extended beneﬁt in these patients.
TableVariableTVT Registry
N[4,913ER/HR Pivotal Study
N[1,030BaselineAge, years / STS PROM, % 81.1 / 8.8 83.0 / 9.2Diabetes, % / Prior CABG, % 38.4 / 30.1 37.9 / 35.8CAD, % / Prior Pacemaker, % 70.1 / 21.8 79.1 / 24.9Mean AV gradient Pre / Post,
mmHg43.3 / 8.4 48.0 / 9.730-Day EventsAll-cause Mortality, % / Any
Stroke, %5.3 / 2.8 6.9 / 5.0Major Vascular, % / New PPM,
%1.1 / 22.3 7.5 / 20.2Device Thrombosis, % /
Fracture, %0 / 0 0 / 0PVL*, % / Valve-in-Valve, % 9.8 / 3.2 10.5 / 2.6Device Implanted Successfully,
%98.0 98.9CABG ¼ coronary artery bypass surgery; CAD ¼ coronary artery disease; STS PROM¼ STS Predicted Risk of
Mortality; *Moderate or severe.
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BACKGROUND The repositionable CoreValve Evolut R transcatheter
aortic valve (TAV) was designed to permit optimal valve placement at
the desired plane of the native aortic valve and depth of implant. The
Evolut R TAV (26, 29 mm) obtained CE marking after demonstrating
safety and efﬁcacy at 30 days in patients with symptomatic aortic
stenosis and heart-team assessed risk of operative mortality. Out-
comes at 1 year will be available at the time of the meeting.
METHODS The Evolut R CE Study included 60 patients implanted at 6
sites in Australia, New Zealand and the United Kingdom and included
the ﬁrst use of the valve for all operators. An independent echocar-
diographic core laboratory was employed, and Clinical Events Com-
mittee adjudicated major adverse events according to Valve Academic
Research Consortium-2 criteria. Major adverse events, functional
improvement, and valve performance were assessed early post-pro-
cedure, at 30 days, 6 months, and 1 year.
RESULTS A total of 60 patients were enrolled and all received the
Evolut R TAV; mean age was 82.8 6.1 years; 66.7% were women,
68.3% had New York Heart Association (NYHA) III/IV symptoms, and
the mean STS-PROM was 7.0%3.7%. The majority of patients (68.3%)
were considered frail. The repositioning feature of the Evolut R was
successfully used 22 times in 15 patients. There were no deaths at 30
days and all-cause mortality at 6 months was 5.0%. One disabling
stroke occurred between 30-day and 6-month follow-up. There were
no valve embolization, migration, endocarditis or thrombosis events,
and no coronary obstruction. The Evolut R TAV effectively treated the
B46 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5aortic stenosis with a mean AV effective oriﬁce area of 1.90.5 cm2
and 1.90.4 cm2; and gradient of 8.13.3 mmHg and 7.63.1 mmHg, at
30 days and 6 months, respectively. Compared with baseline, 76.3% of
patients experienced improvement in NYHA class at 30 days, and
84.9% at 6 months. Permanent pacemaker rates were 11.7% at 30 days,
and 13.4% at 6 months.
CONCLUSIONS The Evolut R TAV is associated with exceptional
safety at 30 days, which continued at 6 months. We plan to report 1-
year outcomes at the time of the meeting.
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BACKGROUND Data on transcatheter aortic valve replacement
(TAVR) failure is limited. The study objective was to determine the
incidence, timing, clinical characteristics and treatment outcomes of
patients diagnosed with TAVR failure attributed to transcatheter heart
valve (THV) thrombosis.
METHODS A retrospective analysis of prospectively raised data
included in a single center TAVR registry. Patients in this 100% follow-
up registry have a predeﬁned echocardiographic and clinical follow-
up schedule (1 month, 6 months,1 year and yearly thereafter or earlier
if symptomatic). THV thrombosis was deﬁned as (1) valve dysfunction
(mean transvalvular gradient >20 mmHg, reduction of the aortic valve
area to <1.2 cm2 or new onset more than mild transvalvular regurgi-
tation) secondary to thrombosis diagnosed based on response to
anticoagulation therapy or typical ﬁndings on imaging modality
(Echo/CT) or (2)mobile mass suspicious of thrombus detected on the
valve, irrespective of dysfunction, and in the absence of infection. The
primary study endpoint was the incidence of THV thrombosis.
RESULTS During the study period (September 2007-March 2015), 588
patients underwent TAVR (CoreValve-305, Sapien XT-124,Sapien 3-
117,Lotus-40,others-2). THV thrombosis was diagnosed in 12(2%) pa-
tients: Sapien XT-9, Sapien3-1 and Lotus-2. Thrombosis was not
observed in any of the CoreValve patients. The mean age was
798years and the majority were females (n¼10, 83.3%). The median
time to thrombosis detection was 180 days(interquartile range, IQR 23-
472). 3 patients were diagnosed early (within 1 month) after TAVR, of
which 2 had a Lotus valve. In another 3 patients, thrombosis was
diagnosed late (>1 year after TAVR). Half of the patients had no wors-
ening symptoms at the time of diagnosis. In symptomatic subjects,
exertional dyspnea with change in NYHA class was the most common
mode of presentation (n¼5). 1 patient presented with stroke. Treatment
at the time of detection of thrombosis was dual antiplatelet therapy in
11 and aspirin monotherapy in 1. No cases of THV thrombosis were seen
in patients discharged on oral anticoagulation. Mean aortic valve
pressure gradient was elevated in 10(83%) of thrombosis patients; mean
transvalvular gradient for all subjects being 3616mmHg. Other echo-
cardiographic ﬁndings included thrombotic mass on the leaﬂets (n¼7,
58.3%) and thickening of leaﬂets with reduced mobility. Median serum
NT-proBNP level was 1318 pg/ml (IQR 1123-1605). After treatment with
anticoagulants, mean aortic gradient and NT-proBNP levels reduced
signiﬁcantly. There were no deaths related to valve thrombosis.
CONCLUSIONS THV thrombosis is a rare but an important cause of
TAVR failure, most frequently detected at a median of 180 days after
the procedure. Patients may present with exertional dyspnoea and/orincreased transvalvular gradients. Anticoagulation is effective in
improving gradients and clinical status. Optimal antithrombotic
therapies after TAVR need to be deﬁned, and randomized controlled
trials are needed.
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BACKGROUND End stage renal disease (ESRD) poses unique chal-
lenges in the treatment of patients with severe aortic stenosis. While
surgical valve replacement in patients with ESRD has been associated
with an increase in the risk of morbidity and mortality, the results
from transcatheter valve replacement have not been clearly deﬁned.
METHODS The CoreValve US Expanded Use Study is a prospective,
nonrandomized trial of transcatheter aortic valve replacement (TAVR)
in extreme risk (ER) patients with ESRD or other speciﬁc comorbidities
excluding them from the Pivotal Trial. Patients with ESRD who were
deemed to be ER by two surgeons, had symptoms attributable to
aortic stenosis, had an aortic valve area of 0.8 cm2 (or aortic valve
area index  0.5 cm2), and either a mean gradient 40 mmHg or peak
velocity  4.0 m/s with one year of follow up are included in this
report. The primary endpoint for the study was all-cause mortality or
major stroke at 12 months. One year outcomes are compared with
patients enrolled in the CoreValve ER US Pivotal Trial and an objective
performance goal (OPG) pre-speciﬁed for the ER US Pivotal Trial.
RESULTS Fifty-four patients with ESRD underwent TAVR with Cor-
eValve as part of the US Expanded Use Study and have reached one year
follow up. Mean STS-PROM was 17.1  8.4 in ESRD patients versus 10.3
 5.5 in ER US Pivotal patients. The rate of all-cause mortality or major
stroke at 12 months was 26% in the ER US Pivotal Trial, 35% in the ESRD
Expanded Use Study, and compared with 43% which is the ER US
Pivotal Objective Performance Goal. Initial 30 day all-cause mortality
was 7.4% (8.4 % in US Pivotal) and 1 year was 35.2% in ESRD patients.
Any stroke or TIA at 1 year was 1.9%, major vascular injury was 3.7% and
new permanent pacemaker rate was 22.9%. Valve performance at one
year was comparable to post-procedure in effective oriﬁce area (1.82
cm2 post-procedure v. 1.81 cm2 1 year) and mean gradient (9.8 mmHg
post-procedure v. 9.2mmHg 1 year).
CONCLUSIONS Early mortality in patients with ESRD is comparable to
ER patients without ESRD but one year data suggest a higher mortality
likely due to comorbid conditions. Stroke and major vascular injury
were infrequent and valve durability is maintained at one year.
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BACKGROUND A peri-procedural stroke rate of 2-7% remains a major
complication after transcatheter aortic valve replacement (TAVR) and
